GE Global Research, a subsidiary of GE Healthcare, has entered into a two-year deal with the National Cancer Institute to develop nanoparticle-based imaging agents. The nanoparticle imaging agents are meant to increase the resolution and sensitivity of imaging devices to allow for earlier detection, monitoring and management of diseases, GE said.

Related Summaries